| |
|
PRESS RELEASE
PrecisionLife Licenses University of Oxford Data to Discover Personalised Treatments for Endometriosis Patients
-
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments for millions of women worldwide.
Oxford, UK, 29 June 2023 – PrecisionLife, a leading techbio company driving precision medicine in complex chronic diseases, announced today a data access agreement with the University of Oxford to license the Oxford Endometriosis Gene (OXEGENE) dataset with the aim to develop new personalised treatments for endometriosis patients.
Endometriosis is a chronic disease associated with severe pain and infertility. It affects 10% of women globally, but how and why it develops is unknown. On average it takes over 7 years for patients to receive a diagnosis and there are currently no approved diagnostic biomarkers or cures for the disease.
The OXEGENE dataset contains anonymised genotype data including disease stage and infertility status, from 1,000 surgically confirmed patients. PrecisionLife's combinatorial analytics platform is unique in its ability to analyse patient data to better understand the causes of complex chronic disease and achieve mechanistic patient stratification to enable precision medicine where it has not previously been possible.
In analysing the OXEGENE data, PrecisionLife hopes to identify the genetic differences in people with endometriosis and the mechanisms driving their disease, to reduce the time to a more personalised diagnosis for patients. PrecisionLife also aims to find novel drug targets for these disease mechanisms with biomarkers linking them to the patients who will benefit from the development of new treatments.
Professor Krina Zondervan, Co-Director of the Endometriosis CaRe Centre and Head of the Nuffield Department of Women’s & Reproductive Health, University of Oxford: “Endometriosis is a major health issue affecting women’s lives. PrecisionLife is a leader in identifying innovative ways to consider the joint effects of combinations of genetic risk variants that may identify biological drivers of complex diseases like endometriosis. We hope that the analysis of our data will lead to the development of precision medicines to improve the lives of patients.”
Dr Steve Gardner, CEO, PrecisionLife: “We're delighted to collaborate with the University of Oxford’s internationally recognised leaders in endometriosis. Our analysis of the OXEGENE dataset will be crucial in replicating our earlier findings and advancing the mechanistic understanding of endometriosis to improve prediction, prevention, and treatment for millions of women around the world.”
PrecisionLife and the University of Oxford are partners in the FEMaLe (Finding Endometriosis using Machine Learning) EU Horizon 2020 project, which aims to enable the delivery of precision medicine in endometriosis and improve quality of life for patients.
In a groundbreaking analysis presented by key opinion leaders at the 15th World Congress on Endometriosis in May 2023, PrecisionLife identified the first biological subtypes of endometriosis, shedding light on distinct patient subgroups defined by combinations of genetic risk factors.
ENDS
Notes to Editors
For further press information please contact:
Noah Konig at PrecisionLife
noah@precisionlife.com / +44 (0)1865 575170
Susie Barber at University of Oxford
susie.barber@wrh.ox.ac.uk / +44 (0)1865 618912
About PrecisionLife
PrecisionLife is a pioneering techbio company changing the way the world predicts, prevents, and treats chronic disease.
Our mission is to find better, more personalized treatment options for patients with unmet medical needs - driving precision medicine beyond oncology and rare diseases, into complex common diseases that account for over 80% of healthcare spending.
Our innovative combinatorial approach allows us to uncover the deepest insights into disease biology and achieve mechanistic patient stratification even in the most heterogeneous conditions.
With a vast repository of information and intellectual property spanning over 45 indications, we have developed one of the most extensive pipelines for precision targeted therapies. This wealth of knowledge empowers us to inform and de-risk every stage of biopharma innovation, from initial concept to the clinic.
To learn more about our groundbreaking work, please visit us at precisionlife.com, connect with us on LinkedIn at @PrecisionLifeAI and follow us on Twitter at @PrecisionLifeAI.
About the Nuffield Department of Women’s & Reproductive Health, University of Oxford
Established in 1937, the Nuffield Department of Women’s & Reproductive Health at the University of Oxford is one of the largest academic departments in the world in its field. The department encompasses multi-disciplinary research across four overarching themes: Cancer, Global Health, Maternal & Fetal Health and Reproductive Medicine & Genetics. Their core purpose is to advance women's and reproductive health through research and teaching, and to improve the quality and delivery of women's healthcare across the globe.
